sCD28, sCD80, sCTLA-4, and sBTLA Are Promising Markers in Diagnostic and Therapeutic Approaches for Aseptic Loosening and Periprosthetic Joint Infection.
Adult
Aged
Aged, 80 and over
Arthroplasty, Replacement, Hip
/ adverse effects
Arthroplasty, Replacement, Knee
/ adverse effects
B7-1 Antigen
/ analysis
Biomarkers
/ analysis
CD28 Antigens
/ analysis
CTLA-4 Antigen
/ analysis
Female
Humans
Joint Prosthesis
Male
Middle Aged
Prosthesis Failure
Prosthesis-Related Infections
/ diagnosis
Receptors, Immunologic
/ analysis
aseptic loosening
immunoregulatory markers
osteoimmunology
periprosthetic joint infection
sBTLA
sCD28
sCD80
sCTLA-4
Journal
Frontiers in immunology
ISSN: 1664-3224
Titre abrégé: Front Immunol
Pays: Switzerland
ID NLM: 101560960
Informations de publication
Date de publication:
2021
2021
Historique:
received:
28
03
2021
accepted:
26
07
2021
entrez:
23
8
2021
pubmed:
24
8
2021
medline:
29
10
2021
Statut:
epublish
Résumé
Aseptic prosthetic loosening and periprosthetic joint infections (PJI) are among the most frequent complications after total knee/hip joint arthroplasty (TJA). Current research efforts focus on understanding the involvement of the immune system in these frequent complications. Different immune cell types have already been implicated in aseptic prosthetic loosening and PJI. The aim of this study was to systematically analyze aspirates from knee and hip joints, evaluating the qualitative and quantitative composition of soluble immunoregulatory markers, with a focus on co-inhibitory and co-stimulatory markers. It has been shown that these molecules play important roles in immune regulation in cancer and chronic infectious diseases, but they have not been investigated in the context of joint replacement. For this purpose, aspirates from control joints (i.e., native joints without implanted prostheses), joints with TJA (no signs of infection or aseptic loosening), joints with aseptic implant failure (AIF; i.e., aseptic loosening), and joints with PJI were collected. Fourteen soluble immunoregulatory markers were assessed using bead-based multiplex assays. In this study, it could be shown that the concentrations of the analyzed immunoregulatory molecules vary between control, TJA, AIF, and PJI joints. Comparing TJA patients to CO patients, sCD80 was significantly elevated. The marker sBTLA was significantly elevated in AIF joints compared to TJA joints. In addition, a significant difference for eight markers could be shown when comparing the AIF and CO groups (sCD27, sCTLA-4, sCD137, sCD80, sCD28, sTIM-3, sPD-1, sBTLA). A significant difference was also reached for nine soluble markers when the PJI and CO groups were compared (sLAG-3, sCTLA-4, sCD27, sCD80, sCD28, sTIM-3, sPD-1, IDO, sBTLA). In summary, the analyzed immunoregulatory markers could be useful for diagnostic purposes as well as to develop new therapeutic approaches for AIF and PJI.
Identifiants
pubmed: 34421900
doi: 10.3389/fimmu.2021.687065
pmc: PMC8377391
doi:
Substances chimiques
B7-1 Antigen
0
Biomarkers
0
CD28 Antigens
0
CTLA-4 Antigen
0
Receptors, Immunologic
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
687065Informations de copyright
Copyright © 2021 Jubel, Randau, Becker-Gotot, Scheidt, Wimmer, Kohlhof, Burger, Wirtz and Schildberg.
Déclaration de conflit d'intérêts
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Références
Rheumatology (Oxford). 2005 Aug;44(8):989-94
pubmed: 15870153
J Arthroplasty. 2018 May;33(5):1309-1314.e2
pubmed: 29551303
Int J Cancer. 2021 Sep 1;149(5):1189-1198
pubmed: 33890289
J Immunol. 2000 May 15;164(10):5015-8
pubmed: 10799854
Mediators Inflamm. 2014;2014:185150
pubmed: 24891761
Immunity. 2009 Apr 17;30(4):482-92
pubmed: 19371714
Clin Immunol. 2007 May;123(2):190-8
pubmed: 17321799
Mol Med. 2018 Jun 18;24(1):32
pubmed: 30134817
Eur J Immunol. 2013 May;43(5):1274-85
pubmed: 23400950
Mol Med Rep. 2016 Aug;14(2):1107-16
pubmed: 27314219
Int Immunol. 2009 Sep;21(9):1037-45
pubmed: 19625381
Front Immunol. 2020 Mar 24;11:487
pubmed: 32265932
Immunity. 2016 May 17;44(5):955-72
pubmed: 27192563
J Bone Joint Surg Am. 2015 Sep 2;97(17):1386-97
pubmed: 26333733
Nat Commun. 2015 Mar 26;6:6692
pubmed: 25809635
PLoS One. 2014 Nov 26;9(11):e95870
pubmed: 25427199
N Engl J Med. 2010 Aug 19;363(8):711-23
pubmed: 20525992
J Immunol. 2006 May 1;176(9):5306-13
pubmed: 16621997
Clin Orthop Relat Res. 2017 Sep;475(9):2194-2201
pubmed: 28573549
J Exp Med. 1988 Oct 1;168(4):1457-68
pubmed: 3049912
Gene Ther. 2004 Feb;11(4):402-7
pubmed: 14724679
Nihon Rinsho. 1995 Oct;53(10):2597-603
pubmed: 8531379
Int Orthop. 2020 Jan;44(1):3-14
pubmed: 31641803
Clin Orthop Relat Res. 2015 Aug;473(8):2700-9
pubmed: 25716213
Oncoimmunology. 2019 Feb 3;8(4):e1561120
pubmed: 30906655
Bone Joint J. 2015 Oct;97-B(10 Suppl A):20-9
pubmed: 26430083
Knee. 2020 Jun;27(3):1101-1105
pubmed: 31806507
Clin Exp Immunol. 2004 May;136(2):388-92
pubmed: 15086406
J Clin Invest. 2015 May;125(5):2046-58
pubmed: 25866972
J Immunother Cancer. 2019 Nov 29;7(1):334
pubmed: 31783776
BMC Immunol. 2019 Aug 7;20(1):27
pubmed: 31390978
Cancer Immunol Immunother. 2015 Oct;64(10):1287-93
pubmed: 25792524
Immunity. 2016 May 17;44(5):1052-68
pubmed: 27192569
Nature. 2002 Oct 24;419(6909):845-9
pubmed: 12397360
J Neuroimmunol. 2002 Sep;130(1-2):224-32
pubmed: 12225905
Int Immunopharmacol. 2012 Dec;14(4):585-92
pubmed: 22917707
Nature. 2006 Sep 21;443(7109):350-4
pubmed: 16921384
Sci Rep. 2020 Feb 25;10(1):3392
pubmed: 32099055
Onco Targets Ther. 2017 Apr 12;10:2147-2154
pubmed: 28442923
Clin Infect Dis. 2007 Nov 1;45(9):1113-9
pubmed: 17918072
Annu Rev Immunol. 2016 May 20;34:539-73
pubmed: 26927206
Biomaterials. 2011 Dec;32(35):9159-67
pubmed: 21872327
Cancer Immunol Res. 2014 Jul;2(7):610-5
pubmed: 24819296
J Immunol. 1991 Oct 15;147(8):2461-6
pubmed: 1717561
Can J Surg. 2020 Jan 29;63(1):E52-E56
pubmed: 31995337
J Immunol. 2006 Dec 15;177(12):8844-50
pubmed: 17142787
J Arthroplasty. 2012 Sep;27(8 Suppl):61-5.e1
pubmed: 22554729
Dtsch Arztebl Int. 2014 Jun 9;111(23-24):407-16
pubmed: 24980673
Scand J Immunol. 2007 Nov;66(5):529-37
pubmed: 17953528
J Bone Joint Surg Am. 2007 Apr;89(4):780-5
pubmed: 17403800
Leuk Lymphoma. 2014 Sep;55(9):2120-4
pubmed: 24283754
J Allergy Clin Immunol. 2010 Feb;125(2 Suppl 2):S33-40
pubmed: 20061006
J Arthroplasty. 2005 Oct;20(7 Suppl 3):46-50
pubmed: 16214002
PLoS One. 2016 Mar 03;11(3):e0150866
pubmed: 26938768
Mol Cell Biol. 2005 Nov;25(21):9543-53
pubmed: 16227604
N Engl J Med. 2009 Aug 20;361(8):787-94
pubmed: 19692690
EFORT Open Rev. 2019 Jul 29;4(7):482-494
pubmed: 31423332
J Immunol. 2013 Sep 1;191(5):2829-36
pubmed: 23918985
Nat Rev Immunol. 2015 Aug;15(8):486-99
pubmed: 26205583
Infect Dis Clin North Am. 2017 Jun;31(2):219-235
pubmed: 28483043
Immunotherapy. 2014;6(10):1073-84
pubmed: 25428646
Cancer Rep (Hoboken). 2019 Aug;2(4):e1160
pubmed: 32721130
Cancer Res. 2012 Feb 15;72(4):917-27
pubmed: 22186141
Arch Orthop Trauma Surg. 2020 Feb;140(2):239-245
pubmed: 31707484
EFORT Open Rev. 2019 Oct 7;4(10):585-594
pubmed: 31754464
Int Orthop. 2014 May;38(5):1077-81
pubmed: 24390010
Cancer Invest. 2010 Oct;28(8):828-32
pubmed: 20482250
PLoS One. 2017 Jan 5;12(1):e0169176
pubmed: 28056053
Tissue Eng Regen Med. 2019 Jul 26;16(4):327-334
pubmed: 31413937
J Exp Med. 2009 Dec 21;206(13):3015-29
pubmed: 20008522
Proc Natl Acad Sci U S A. 2009 Apr 14;106(15):6303-8
pubmed: 19332785
Scand J Immunol. 2003 Jun;57(6):568-72
pubmed: 12791095
J Immunother Cancer. 2018 Nov 27;6(1):132
pubmed: 30482248
Rev Immunogenet. 1999;1(1):32-46
pubmed: 11256571
J Viral Hepat. 2019 Aug;26(8):942-950
pubmed: 30972915
Curr Biol. 1995 Aug 1;5(8):866-8
pubmed: 7583143
J Viral Hepat. 2019 Jul;26(7):795-802
pubmed: 30578715
Int Arch Allergy Immunol. 2005 May;137(1):45-52
pubmed: 15785081
Science. 1996 Mar 22;271(5256):1734-6
pubmed: 8596936